II型高リポ蛋白血症患者におけるProbucol(500mg 1日)投与の影響

DOI Web Site

書誌事項

タイトル別名
  • Effects of Probucol on Serum Lipids, Lipoprotein Lipids, Serum α-Tocopherol and Serum Coenzyme Q<sub>10</sub> in Patients with Type II Hyperlipoproteinemia
  • Effects of Probucol on Serum Lipids, Lipoprotein Lipids, Serum &alpha;-Tocopherol and Serum Coenzyme Q<sub>10</sub> in Patients with Type II Hyperlipoproteinemia

抄録

The effects of probucol on serum lipids, lipoprotein lipids, serum α-tocopherol and Co-Q10 were studied in 28 patients with type II hyperlipo-proteinemia.<br>The patients received 2×250mg of probucol per day for 16 weeks.<br>Total cholesterol, triglyceride and phospholipid were significantly reduced with probucol (20%, 17%, 18% respectively). LDL and HDL cholesterol were also reduced significantly (14%, 10% respectively), but atherogenic index (VLDL+LDL-Ch/HDL-Ch) was not significantly changed. The extent of the fall in total cholesterol was directly proportional to the pre-treatment total cholesterol level, the higher this level the greater the decrement. HDL-cholesterol fell by 46% in patients whose pre-treatment HDL-cholesterol levels were over 50mg/dl, but did not fall in patients whose pretreatment levels were under 40mg/dl.<br>There was no significant change in serum α-tocopherol-concentration.<br>Serum Coenzyme Q10 concentration were significantly reduced from 1, 765±308μg/ml to 1, 109±153μg/ml. Generally the drug was well accepted and free of significant toxic effects.<br>These results suggested that probucol in a dose of 500mg/day appeared to be useful for the treatment in patients with type II hyperlipoproteinemia.

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ